The prognostic value of pain in castration-sensitive prostate cancer

Iacovelli, Roberto; Ciccarese, Chiara; Caffo, Orazio; Giorgi, Ugo De; Tucci, Marco; Mandato, Claudia; Bimbatti, Davide; Pierantoni, Francesco; Maines, Francesca; Casadei, Chiara; Buttigliero, Consuelo; Milella, Michele Stanislaw

doi:10.1038/s41391-020-0255-x

Cited by 9 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we could not analyze the correlation between LDH levels and the prognosis of mHNPC patients because the LDH assay kit was different for each facility. Besides, pain at baseline has also been reported as a significant prognostic factor among patients with mHNPC 27 . Unfortunately, this information was not included in our MPCG database.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Besides, pain at baseline has also been reported as a significant prognostic factor among patients with mHNPC. 27 Unfortunately, this information was not included in our MPCG database.…”

Section: Discussionmentioning

confidence: 99%

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Prostate cancer progression in phase III mCRPC trials is consistently defined by progression of measurable lesions (as per RECIST), or appearance of new bone lesions, or confirmed rising PSA (as per PCWG 2 or 3 criteria) [23,31]. We believe this definition of disease progression is insufficient because it does not take into account pain progression, which is a major prognostic factor consistently associated with features of aggressive disease in mCRPC as well as in mCSPC [32]. Moreover, there is increasing evidence that many patients do not follow the sequence of progression events model initially described [28]: "PSA progression" as the first progression event to occur during therapy, followed by "radiological progression", followed by "clinical progression".…”

Section: Discussionmentioning

confidence: 99%

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study

Delanoy

Robbrecht

Eisenberger

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: In the PROSELICA phase III trial (NCT01308580), cabazitaxel 20 mg/m2 (CABA20) was non-inferior to cabazitaxel 25 mg/m2 (CABA25) in mCRPC patients previously treated with docetaxel (DOC). The present post hoc analysis evaluates how the type of progression at randomization affected outcomes. Methods: Progression type at randomization was defined as follows: PSA progression only (PSA-p; no radiological progression (RADIO-p), no pain), RADIO-p (±PSA-p, no pain), or pain progression (PAIN-p, ±PSA-p, ±RADIO-p). Relationships between progression type and overall survival (OS), radiological progression-free survival (rPFS), and PSA response (confirmed PSA decrease ≥ 50%) were analyzed. Results: All randomized patients (n = 1200) had received prior DOC, and 25.7% had received prior abiraterone or enzalutamide. Progression type at randomization was evaluable in 1075 patients (PSA-p = 24.4%, RADIO-p = 20.8%, PAIN-p = 54.8%). Pain progression was associated with clinical and biological features of aggressive disease. Median OS from CABA initiation or date of mCRPC diagnosis, all arms combined, was shorter in the PAIN-p group than in the RADIO-p or the PSA-p groups (12.0 versus 16.8 and 18.4 months, respectively, p < 0.001). In multivariate analysis, all arms combined, PAIN-p was an independent predictor of poor OS (HR = 1.44, p < 0.001). PSA response, rPFS, and OS were numerically higher with CABA25 versus CABA20 in patients with PAIN-p. Conclusions: This post hoc analysis of the PROSELICA phase III study shows that pain progression at initiation of CABA in mCRPC patients previously treated with DOC is associated with a poor prognosis. Disease progression should be carefully monitored, even in the absence of PSA rise.

show abstract

“…Prostate cancer (PCa) is a malignant tumor caused by excessive proliferation of prostatic epithelial cells [1]. Its morbidity is the second highest among male malignant tumors [2].…”

Section: Introductionmentioning

confidence: 99%

Krüppel-like factor 8 promotes aerobic glycolysis in prostate cancer cells by regulating AKT/mTOR signaling pathway

Zhang¹,

Chen²,

Song³

et al. 2020

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the effects of Krüppel-like factor 8 (KLF8) in prostate cancer (PCa) cell viability and glycolysis, and explore its role as a regulatory factor.Methods: Immunoblot assays were conducted to assess the expression of KLF8 and proteins in AKT/mTOR pathway in PCa cell lines PC-3 and DU145. Cell Counting Kit-8 assays were performed to assess the effect of KLF8 on PCa cell viability. The glycolysis capacity of PCa cells was determined by measuring the levels of glucose intake, lactic acid production, and cellular ATP levels.Results: Depletion of KLF8 decreased the survival of PCa cells in vitro (p < 0.05). KLF8 depletion also inhibited aerobic glucose metabolism in PCa cells (p < 0.05). Further studies confirmed that KLF8 contributed to the growth and glycolysis of PCa cells via the regulation of AKT/mTOR pathway.Conclusion: KLF8 regulates glycolysis in PCa cells by regulating AKT/mTOR signaling pathway and is thus a promising therapeutic target for PCa treatment. Keywords: Krüppel-like factor 8 (KLF8), Prostate cancer (PCa), Aerobic glucose, AKT/mTOR signaling pathway, Therapeutic target

show abstract

The prognostic value of pain in castration-sensitive prostate cancer

Cited by 9 publications

References 20 publications

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study

Krüppel-like factor 8 promotes aerobic glycolysis in prostate cancer cells by regulating AKT/mTOR signaling pathway

Contact Info

Product

Resources

About